ArticleJournal of translational medicine2026
CCL5 improves radiation resistance through activation of the AMPK/mTOR pathway in adenoid cystic carcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHead and neck adenoid cystic carcinoma (HNACC) is an uncommon but aggressive salivary gland malignancy with high recurrence and metastasis rates. Its "immune-cold" phenotype limits the efficacy of systemic therapy, and thus, radiotherapy is the principal treatment for unresectable cases. However, frequent radioresistance suggests the involvement of distinct molecular drivers. This study investigated the role of CCL5 in HNACC radioresistance, its mechanistic link to autophagy, and its potential as a radiosensitization target.
methodsTranscriptome sequencing of radiation-sensitive (SACC-83) and radiation-tolerant (SACC-LM) cell lines, integrated with GEO datasets, identified candidate genes. For functional validation, genetic manipulation and pharmacological inhibition with the CCL5/CCR5 antagonist maraviroc were performed. Cellular proliferation, invasion, apoptosis, cell cycle, and radiosensitivity were assessed. Autophagy was examined by transmission electron microscopy and western blotting, with a focus on AMPK/mTOR signaling. A xenograft mouse model was used to evaluate the therapeutic effect of maraviroc combined with radiotherapy.
resultsCCL5 expression was elevated in radioresistant cells and further induced by irradiation. High CCL5 levels promoted proliferation, migration, and invasion while reducing radiation-induced apoptosis and G₂/S arrest. Mechanistically, CCL5 activated AMPK, suppressed mTOR, and enhanced autophagy, supporting cell survival under radiation stress. CCL5 inhibition reduced autophagy, restored radiosensitivity, and synergized with irradiation, whereas autophagy activation reversed these effects. In vivo, maraviroc combined with radiotherapy decreased tumor burden, suppressed CCL5 expression, and inhibited autophagy.
conclusionCCL5 promotes radioresistance in HNACC through maintenance of AMPK/mTOR-dependent autophagy. Targeting the CCL5/CCR5 axis enhances radiosensitivity and represents a promising therapeutic strategy. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.